Solid Neoplasms Clinical Trial
Official title:
Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with pembrolizumab.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04078295 -
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02896049 -
Celsius TCS Hyperthermia System PMCF Trial
|
||
Active, not recruiting |
NCT03833700 -
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
|
Phase 1 | |
Recruiting |
NCT04407676 -
Improving Informed Consent for Early Phase Anti-Cancer Trials
|
N/A | |
Recruiting |
NCT04420884 -
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01543282 -
Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles
|
N/A |